RICHMOND HILL, ON, Dec. 23, 2013 /CNW/ - Finnish healthcare company
Biohit Oyj is restructuring its distribution regarding Acetium products
in Canada and therefore has signed a distribution agreement with
Canadian company Medical Futures Inc. The agreement is effective
immediately and will replace the previous distribution agreement.
Within the agreement, Medical Futures Inc. gains exclusive rights for
the distribution of Acetium capsules and lozenges in Canada.
The L-cysteine in Acetium capsules dissolves slowly into the gastric
fluid, efficiently binding (neutralising) carcinogenic acetaldehyde in
an achlorhydric stomach. This contributes to the prevention of cancer
in the mouth, stomach and oesophagus. Acetium capsules are intended
e.g. for PPI users and persons suffering from an achlorhydric stomach
caused by atrophy of the gastric mucosa and functional disorder
(atrophic gastritis). An anacidic stomach is the most significant risk
factor for stomach and oesophageal cancer. (1).
The Acetium lozenge is intended for smokers to bind acetaldehyde that
dissolves in saliva during smoking. Acetaldehyde is the most important
carcinogen in cigarette smoke. (2,3).
CEO Semi Korpela, Biohit Oyj: "Acetium capsules help to reduce
carcinogenic acetaldehyde in the stomachs of patients who have
hypoacidic or anacidic stomachs, or, who use antacid medication (i.e.
proton pump inhibitors and H2-receptor antagonists) through the slow
and local release of L-cystein, now also available in Canada. The
Acetium lozenge will be registered in the next phase".
CEO Lee Ferreira, Medical Futures Inc.: "We look forward to our
partnership with Biohit Oyj and to providing Canadians with access to
Acetium. With acetaldehyde exposure linked to approximately four
million new cases of cancer globally, each year, this innovative
product will address the needs of many individuals seeking an option to
reduce this carcinogen".
(1) Sipponen P et al (1985) Gastric cancer risk in chronic atrophic
gastritis: statistical calculations of cross-sectional data. Int J
(2) Haussmann H-J (2012) Use of hazard indices for a theoretical
evaluation of cigarette smoke composition. Chem Res Toxicol
(3) Burns DM et al (2008) Mandated lowering of toxicants in cigarette
smoke: a description of the World Health Organization TobReg proposal.
Tob Control 2008;17:132-41.
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company
established in 1988. Biohit's mission is "Innovating for Health". The
purpose of the company is to take social responsibility and produce
innovation, new technologies and analysis systems for use in medicine,
research institutions and industry, helping to promote research and
diagnostics and to improve the quality of life of people by preventing
disease, human suffering and financial loss. We are committed to social
responsibility and it is our duty to spread knowledge about the Group I
human carcinogen, acetaldehyde, and innovate and develop the marketing
and availability of our products and services. Biohit is headquartered
in Helsinki, Finland and its subsidiaries are located in Italy and the
United Kingdom. Since 1999, Biohit's series B shares (BIOBV) have been
listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com
Medical Futures Inc. in brief
Medical Futures Inc. is a niche pharmaceutical company with a focus on
Gastroenterology, Pain Management, Dermatology and Women's Health. We
provide Canadians with safe, effective and affordable products to help
improve the overall quality of their lives. http://medfutures.com/
SOURCE: Medical Futures Inc.
For further information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861